scholarly journals Association of Sleep paralysis with Insomnia and Sleep Quality

2021 ◽  
Vol 6 (3) ◽  
Author(s):  
Azal Ikhlaq
SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A192-A193
Author(s):  
Michael Thorpy ◽  
Thomas Roth ◽  
Yves Dauvilliers ◽  
Clete Kushida ◽  
Colin Shapiro ◽  
...  

Abstract Introduction Sodium oxybate (SO) is an effective treatment for narcolepsy; however, currently available formulations must be taken twice nightly. FT218 is an investigational once-nightly controlled-release formulation of SO. Here, we evaluated the efficacy of FT218 on excessive daytime sleepiness (EDS), self-reported sleep quality/refreshing nature of sleep, sleep paralysis (SP), and hypnagogic hallucinations (HH) in patients with narcolepsy. Methods In this phase 3, randomized, double-blind, placebo-controlled, multicenter study, patients aged ≥16 years with narcolepsy type 1 or 2 were randomized 1:1 to receive FT218 or matching placebo: 4.5 g/night (1 week), 6.0 g/night (2 weeks), 7.5 g/night (5 weeks), and 9.0 g/night (5 weeks). Secondary efficacy endpoints included EDS using the Epworth Sleepiness Scale (ESS), sleep quality/refreshing nature of sleep using a visual analog scale (VAS), and SP and HH using a sleep symptom diary. Results A total of 212 patients were randomized and received study medication (FT218, n=107; placebo, n=105). Patients receiving FT218 had significant improvement vs placebo in EDS on the ESS: LS mean difference on ESS score between FT218 and placebo was −3.86 for 9.0 g (week 13), −3.16 for 7.5 g (week 8), and −2.06 for 6.0 g (week 3) (all P<0.001). Sleep quality/refreshing nature of sleep on VAS was also significantly improved with FT218 vs placebo (P<0.001 for all doses). Patients receiving FT218 reported less SP vs placebo (P<0.05 at all doses). Baseline values for HH were low in both treatment groups; HH was similar for both treatment groups at all study visits. The most common adverse reactions were nausea, dizziness, enuresis, headache, decreased appetite, and vomiting. Conclusion At all evaluated doses, treatment with FT218 significantly improved EDS, sleep quality/refreshing nature of sleep, and SP vs placebo. FT218 was generally well tolerated; the most common adverse events were consistent with known SO side effects. Support (if any) Avadel Pharmaceuticals.


2016 ◽  
Vol 27 (4) ◽  
pp. 231-243 ◽  
Author(s):  
Bernd Kundermann ◽  
Stanislava Fockenberg ◽  
Nicole Cabanel ◽  
Matthias J. Müller

Zusammenfassung. Die Beziehung zwischen kognitiven Defiziten und Schlafstörungen depressiver Patienten wurde bisher wenig untersucht. Stationär behandelte depressive Patienten beantworteten Fragebögen zur Depressivität und Schlafqualität (Pittsburgh Sleep Quality Inventory, PSQI), gefolgt von neuropsychologischen Untersuchungen zu attentional-exekutiven Funktionsleistungen (Trail Making Test: TMT-A, TMT-B) an Tag 1 (abends) und Tag 2 (morgens). Patienten mit schweren Schlafstörungen (PSQI > 10, n = 8) erbrachten gegenüber Patienten mit maximal moderat ausgeprägten Schlafstörungen (PSQI ≤ 10, n = 8) signifikant geringere Leistungen im Rahmen des TMT-A und TMT-B. Signifikante positive Korrelationen zwischen dem Globalwert des PSQI und der TMT-B-Bearbeitungszeit blieben auch unter statistischer Berücksichtigung von Kovariaten erhalten. Diese Ergebnisse unterstreichen die enge Beziehung zwischen kognitiven Dysfunktionen und Schlafstörungen bei depressiven Patienten. Mögliche therapeutische Implikationen werden diskutiert.


Dreaming ◽  
2003 ◽  
Vol 13 (3) ◽  
pp. 163-179
Author(s):  
J. A. Cheyne
Keyword(s):  

2019 ◽  
Vol 33 (3) ◽  
pp. 266-273 ◽  
Author(s):  
Rowan P. Ogeil ◽  
Ali Cheetham ◽  
Anna Mooney ◽  
Nicholas B. Allen ◽  
Orli Schwartz ◽  
...  

2003 ◽  
Author(s):  
D. K. Thomsen ◽  
M. Y. Mehlsen ◽  
S. Christensen ◽  
R. Zachariae
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document